Form 4: ADMA Biologics Director Alison Finger Reports Stock and Option Transactions

Alison Finger, a director at ADMA Biologics, reported the acquisition of restricted stock units and stock options, as well as the disposal of common stock.

Summary

• On February 19, 2025, Alison Finger, a director of ADMA Biologics, reported transactions involving the company's securities.
• Finger acquired 10,889 restricted stock units (RSUs) and 16,279 stock options.
• The RSUs vest in two equal installments over a year.
• The stock options vest in 12 equal monthly installments over a year.
• Finger also disposed of common stock.
• Following these transactions, Finger beneficially owns 34,929 shares of common stock.
• A Limited Power of Attorney was executed on March 28, 2024, granting Adam S. Grossman and Michael A. Goldstein the authority to act on Finger's behalf for Section 16(a) reporting.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral. It reflects insider transactions, which could be interpreted in various ways depending on the investor's perspective.

Positives

• The acquisition of RSUs and stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Negatives

• The disposal of common stock by the director could be interpreted negatively by some investors.

Risks

• The vesting schedules of the RSUs and stock options are subject to the Reporting Person's continued service, creating a potential risk if service is terminated before full vesting.

Industry Context

This filing is a routine disclosure required by the SEC for insiders of publicly traded companies, providing transparency into their transactions in the company's stock.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders.
• The vesting schedules for RSUs and stock options are typical in executive compensation packages.

Stakeholder Impact

• Shareholders may react to the reported transactions, potentially influencing the stock price.

Key Dates

Keywords

ADMA Biologics, Form 4, Section 16(a), Alison Finger, Restricted Stock Units, Stock Options, Beneficial Ownership, Director, Securities Exchange Act